Get the Stockscreener App
1.71
1.16%
-0.02
After Hours:
1.70
-0.01
-0.58%
Cardiol Therapeutics Inc stock is traded at $1.71, with a volume of 889.56K.
It is down -1.16% in the last 24 hours and down -14.50% over the past month.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
See More
Previous Close:
$1.73
Open:
$1.7499
24h Volume:
889.56K
Relative Volume:
0.77
Market Cap:
$207.79M
Revenue:
-
Net Income/Loss:
$-26.33M
P/E Ratio:
-6.0552
EPS:
-0.2824
Net Cash Flow:
$-17.65M
1W Performance:
-8.80%
1M Performance:
-14.50%
6M Performance:
+59.81%
1Y Performance:
+58.33%
1-Day Range:
$1.67
$1.75
1-Week Range:
$1.66
$1.955
52-Week Range:
$0.88
$2.34
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.71 | 207.79M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early - the deep dive
Cardiol Therapeutics Inc. (CRDL.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cardiol Therapeutics Inc. (CRDL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cardiol Therapeutics Slides Under Pressure: Clinical-Stage Uncertainty and Shelf Prospectus Overhang Weigh on Investor Sentiment - kalkine.ca
Cardiol Therapeutics Inc (CRDL) Stock Price Target & Forecast - TradingKey
Cardiol Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co. - Moomoo
Tejara Capital Holds 5.3% Stake in Cardiol Therapeutics (NASDAQ: CRDL), Owning 6.38 Million Shares - Kalkine Media
CRDL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $9.00 - GuruFocus
Fund manager reports 6.4M Cardiol Therapeutics (NASDAQ: CRDL) shares - Stock Titan
HC Wainwright & Co. reiterates Buy rating on Cardiol Therapeutics, $9 price target - TradingView
Cardiol expands phase III trial enrollment to 150 patients By Investing.com - Investing.com Nigeria
Cardiol Therapeutics (CRDL) Advances MAVERIC Phase III Trial, Ma - GuruFocus
Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone - TipRanks
Cardiol expands phase III trial enrollment to 150 patients - Investing.com India
Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy - TradingView
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy - PR Newswire
Why Are Markets Watching Cardiol Therapeutics (TSX:CRDL) Midcap Shares? - kalkinemedia.com
Cardiol Therapeutics Inc. (TSX:CRDL): A Fresh Healthcare Stocks Catalyst Today - Kalkine Media
Cardiol Therapeutics Inc. (TSX:CRDL) Back In Focus For Growth Stocks Watchers - Kalkine Media
Cardiol Therapeutics Inc. (TSX:CRDL): Today's Cannabis Stocks Story - kalkinemedia.com
Cardiol Therapeutics (Nasdaq: CRDL) opens path to raise cash for heart drug trials - Stock Titan
Cardiol Therapeutics (CRDL) Raises $7M via Warrants, Extends Run - GuruFocus
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds - PR Newswire
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Declines 6.86% as Selling Pressure Builds - kalkine.ca
New conduct code at Cardiol Therapeutics (CRDL) tightens conflict, confidentiality and whistleblower rules - Stock Titan
WHY TerrAscend (TSX:TSND), Cardiol Therapeutics Inc. (TSX:CRDL), Vizsla Royalties (TSXV:VROY), Quarterhill (TSX:QTRH) and GoldMining (TSX:GOLD) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca
CRDL: Phase III data readout and expansion into heart failure set the stage for broad market impact - TradingView
Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For MAVERIC (NASDAQ:CRDL) - Seeking Alpha
CRDL: Cardiol Therapeutics IncOrdinary SharesClass A Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Cardiol Therapeutics (TSX:CRDL) Slides 12.34% as Volatility Returns and Investors Reassess the Clinical-Stage Risk - kalkine.ca
Cardiol Therapeutics Stock Faces Renewed Pressure as Biotech Risk and Clinical Uncertainty Weigh on Sentiment - kalkine.ca
Cardiol Therapeutics (CRDL) sets terms with new manufacturing and drug ingredient partners - Stock Titan
Cardiol Therapeutics files $150 million shelf prospectus By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus - TradingView
Cardiol Therapeutics files $150 million shelf prospectus - investing.com
New 25‑month shelf lets Cardiol Therapeutics (CRDL) line up future financing - Stock Titan
Cardiol Therapeutics files US$150M base shelf prospectus - tradingview.com
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission - PR Newswire
Cardiol Therapeutics Inc. (NASDAQ: CRDL) to Host Fireside Chat on September 14 at H.C. Wainwright Investment Conference - Kalkine Media
Cardiol Therapeutics (NASDAQ: CRDL) lines up new shelf to fund drug trials - Stock Titan
Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln - tradingview.com
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Gains Momentum as Cardiovascular Drug Pipeline Progress Strengthens Investor Optimism - kalkine.ca
Cardiol Therapeutics (TSX:CRDL) Healthcare Stock Latest Update - Kalkine Media
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Heart-drug developer Cardiol Therapeutics (CRDL) heads to a major New York investor conference - Stock Titan
Cardiol Therapeutics will join a heart-disease drug chat in New York Sept. 14 - Stock Titan
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Cardiol Therapeutics to present at H.C. Wainwri... - Pluang
Cardiol Therapeutics Inc Class A (CRDL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cardiol Therapeutics Inc. (TSX:CRDL) Climbs 10.18% as Phase III Catalyst and CardiolRx Momentum Strengthen Investor Optimism - kalkine.ca
Cardiol Therapeutics Inc Class A (CRDL) Peer Comparison – Compare with Others - Value Research
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):